title: Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab.
abstract: OBJECTIVE
  To assess the association between a single nucleotide polymorphism in the gene of FCGR3A and the response to treatment with rituximab (RTX) in rheumatoid arthritis (RA).
  
  
  METHODS
  SMART is a randomised open trial assessing two strategies of re-treatment in patients responding to 1 g infusion of RTX with methotrexate on days 1 and 15 after failure, intolerance or contraindication to tumour necrosis factor (TNF) blockers. Among the 224 patients included, 111 could be genotyped and were included in an ancillary study of SMART. Univariate and multivariate analyses adjusted on disease activity score on 28 joints were performed to assess whether FCGR3A-158V/F polymorphism was associated with European League Against Rheumatism response at week 24.
  
  
  RESULTS
  Among the 111 patients, 90 (81%) were responders of whom 30 (27%) were good responders. V allele carriage was significantly associated with a higher response rate (91% of responders vs 70%, OR 4.6 (95% CI 1.5 to 13.6), p=0.006). These results were also confirmed in rheumatoid factor-positive patients (93% vs 74%, p=0.025). In multivariate analysis, V allele carriage was independently associated with response to RTX (OR 3.8 (95% CI 1.2 to 11.7), p=0.023).
  
  
  CONCLUSIONS
  The 158V/F polymorphism of FCGR3A seems to influence the response to RTX in patients with RA after failure, intolerance or contraindication to TNF blockers.
authors.affiliation: Department of Rheumatology, Purpan Teaching Hospital, Toulouse, UMR U1027 INSERM, UMR 1027, Université Paul Sabatier, Toulouse III, France. adruyssen@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Ruyssen-Witrand
authors.forename: S
authors.initials: S
authors.lastname: Rouanet
authors.forename: B
authors.initials: B
authors.lastname: Combe
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: X
authors.initials: X
authors.lastname: Le Loët
authors.forename: J
authors.initials: J
authors.lastname: Sibilia
authors.forename: J
authors.initials: J
authors.lastname: Tebib
authors.forename: X
authors.initials: X
authors.lastname: Mariette
authors.forename: A
authors.initials: A
authors.lastname: Constantin
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D004351:Drug Resistance / Q000235:genetics*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D017452:Receptors, IgG / Q000235:genetics*; D000069283:Rituximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D008727:Methotrexate